重症和极重症COVID-19患者的静脉血栓栓塞并发症

M. V. Bychinin, I. Mandel, T. Klypa, P. Avdonin, D. I. Korshunov, T.S. Bobrovitskaya, S. A. Andreichenko
{"title":"重症和极重症COVID-19患者的静脉血栓栓塞并发症","authors":"M. V. Bychinin, I. Mandel, T. Klypa, P. Avdonin, D. I. Korshunov, T.S. Bobrovitskaya, S. A. Andreichenko","doi":"10.17116/anaesthesiology202104141","DOIUrl":null,"url":null,"abstract":"Objective. To analyze the incidence and predictors of venous thromboembolic complications (VTEC) in COVID-19 patients ad-mitted to intensive care unit (ICU). Material and methods. A retrospective study recruited 200 ICU patients presenting with severe or critical COVID-19. Results. VTEC were found in 67 (33.5%) out of 200 patients. In 63 patients, deep and superficial vein thrombosis was observed. Four patients had pulmonary embolism. In 41 (20.5%) patients, VTEC occurred within the first day after admission to ICU. Patients presenting with VTEC had more extensive lung damage (CT data) and more common need for vasopressors (79.1% vs 59.4%, p=0.005) and mechanical ventilation (89.6% vs 60.2%, p=0.0001). Survival of these patients was lower (23 (34.3%) vs 76 (57.1%), p=0.003). There were significant differences in levels of von Willebrand factor antigen (vWF: Ag), interleukin 6 (IL-6), antithrombin III (AT III) and protein C. According to ROC analysis, vWF: Ag above 455% (AUC — 0.852 (0.69;1.00), p=0.008) was highly predictive for the risk of VTEC after 1 and 7 days. AT III below 72% (AUC — 0.77 (0.55;0.99), p=0.04) and IL-6 above 256 pg/ml (AUC — 0.85 (0.65;1.00), p=0.053) were prognostic factors of VTEC after the first day. Protein C below 81.5% at admission (AUC — 0.79 (0.59-0.99), p=0.042) was predictive regarding VTEC by the seventh day. Conclusion. Incidence of VTEC in ICU patients was 33.5%. In 60% of patients, VTEC developed before admission to ICU. vWF: Ag, AT III, IL-6, and protein C serve as predictors of VTEC in patients with severe or critical COVID-19. © 2021, Media Sphera Publishing Group. All rights reserved.","PeriodicalId":297480,"journal":{"name":"Anesteziologiya i reanimatologiya","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Venous thromboembolic complications in patients with severe and extremely severe COVID-19\",\"authors\":\"M. V. Bychinin, I. Mandel, T. Klypa, P. Avdonin, D. I. Korshunov, T.S. Bobrovitskaya, S. A. Andreichenko\",\"doi\":\"10.17116/anaesthesiology202104141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective. To analyze the incidence and predictors of venous thromboembolic complications (VTEC) in COVID-19 patients ad-mitted to intensive care unit (ICU). Material and methods. A retrospective study recruited 200 ICU patients presenting with severe or critical COVID-19. Results. VTEC were found in 67 (33.5%) out of 200 patients. In 63 patients, deep and superficial vein thrombosis was observed. Four patients had pulmonary embolism. In 41 (20.5%) patients, VTEC occurred within the first day after admission to ICU. Patients presenting with VTEC had more extensive lung damage (CT data) and more common need for vasopressors (79.1% vs 59.4%, p=0.005) and mechanical ventilation (89.6% vs 60.2%, p=0.0001). Survival of these patients was lower (23 (34.3%) vs 76 (57.1%), p=0.003). There were significant differences in levels of von Willebrand factor antigen (vWF: Ag), interleukin 6 (IL-6), antithrombin III (AT III) and protein C. According to ROC analysis, vWF: Ag above 455% (AUC — 0.852 (0.69;1.00), p=0.008) was highly predictive for the risk of VTEC after 1 and 7 days. AT III below 72% (AUC — 0.77 (0.55;0.99), p=0.04) and IL-6 above 256 pg/ml (AUC — 0.85 (0.65;1.00), p=0.053) were prognostic factors of VTEC after the first day. Protein C below 81.5% at admission (AUC — 0.79 (0.59-0.99), p=0.042) was predictive regarding VTEC by the seventh day. Conclusion. Incidence of VTEC in ICU patients was 33.5%. In 60% of patients, VTEC developed before admission to ICU. vWF: Ag, AT III, IL-6, and protein C serve as predictors of VTEC in patients with severe or critical COVID-19. © 2021, Media Sphera Publishing Group. All rights reserved.\",\"PeriodicalId\":297480,\"journal\":{\"name\":\"Anesteziologiya i reanimatologiya\",\"volume\":\"2 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anesteziologiya i reanimatologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17116/anaesthesiology202104141\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesteziologiya i reanimatologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/anaesthesiology202104141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

目标。目的分析2019冠状病毒病疫情(COVID-19)重症监护病房(ICU)患者静脉血栓栓塞并发症(VTEC)的发生率及预测因素。材料和方法。一项回顾性研究招募了200名重症或危重型COVID-19 ICU患者。结果。200例患者中有67例(33.5%)出现VTEC。63例患者出现深、浅静脉血栓形成。4例患者有肺栓塞。41例(20.5%)患者在入住ICU后第一天内发生VTEC。出现VTEC的患者有更广泛的肺损伤(CT数据),更需要血管加压剂(79.1% vs 59.4%, p=0.005)和机械通气(89.6% vs 60.2%, p=0.0001)。这些患者的生存率较低(23例(34.3%)vs 76例(57.1%),p=0.003)。血管性血友病因子抗原(vWF: Ag)、白细胞介素6 (IL-6)、抗凝血酶III (AT III)、蛋白c水平差异有统计学意义。ROC分析显示,vWF: Ag在455%以上(AUC - 0.852 (0.69;1.00), p=0.008)对第1、7天发生VTEC的风险具有高度预测作用。atiii低于72% (AUC - 0.77 (0.55;0.99), p=0.04)、IL-6高于256 pg/ml (AUC - 0.85 (0.65;1.00), p=0.053)是第1天后VTEC的预后因素。入院时蛋白C低于81.5% (AUC - 0.79 (0.59-0.99), p=0.042)可预测第7天的VTEC。结论。ICU患者VTEC发生率为33.5%。60%的患者在进入ICU前出现VTEC。vWF: Ag、AT III、IL-6和蛋白C可作为重型或危重型COVID-19患者VTEC的预测指标。©2021,Media Sphera出版集团。版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Venous thromboembolic complications in patients with severe and extremely severe COVID-19
Objective. To analyze the incidence and predictors of venous thromboembolic complications (VTEC) in COVID-19 patients ad-mitted to intensive care unit (ICU). Material and methods. A retrospective study recruited 200 ICU patients presenting with severe or critical COVID-19. Results. VTEC were found in 67 (33.5%) out of 200 patients. In 63 patients, deep and superficial vein thrombosis was observed. Four patients had pulmonary embolism. In 41 (20.5%) patients, VTEC occurred within the first day after admission to ICU. Patients presenting with VTEC had more extensive lung damage (CT data) and more common need for vasopressors (79.1% vs 59.4%, p=0.005) and mechanical ventilation (89.6% vs 60.2%, p=0.0001). Survival of these patients was lower (23 (34.3%) vs 76 (57.1%), p=0.003). There were significant differences in levels of von Willebrand factor antigen (vWF: Ag), interleukin 6 (IL-6), antithrombin III (AT III) and protein C. According to ROC analysis, vWF: Ag above 455% (AUC — 0.852 (0.69;1.00), p=0.008) was highly predictive for the risk of VTEC after 1 and 7 days. AT III below 72% (AUC — 0.77 (0.55;0.99), p=0.04) and IL-6 above 256 pg/ml (AUC — 0.85 (0.65;1.00), p=0.053) were prognostic factors of VTEC after the first day. Protein C below 81.5% at admission (AUC — 0.79 (0.59-0.99), p=0.042) was predictive regarding VTEC by the seventh day. Conclusion. Incidence of VTEC in ICU patients was 33.5%. In 60% of patients, VTEC developed before admission to ICU. vWF: Ag, AT III, IL-6, and protein C serve as predictors of VTEC in patients with severe or critical COVID-19. © 2021, Media Sphera Publishing Group. All rights reserved.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Intraoperative and early postoperative respiratory function in patients with coronary artery disease undergoing on-pump or off-pump coronary artery bypass surgery Programmed intermittent epidural bolus (PIEB) for labor pain relief Patient blood management in orthopedic surgery Nitric oxide application for myocardial protection in coronary artery disease Levosimendan and phosphocreatin administration for correction of myocardial ischemic - reperfusion injury: experimental research ex vivo
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1